AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01218672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoselective Vaporization of the Prostate
Description: GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.~GreenLight XPS will be used in conjunction with the MoXy™ fiber. The fiber features a side firing mechanism delivering up to180W of 532 nm light to vaporize and coagulate the prostate tissue. The fiber is guided to the treatment site by the continuous flow cystoscope, consisting of an inner and outer sheath set, 30ْ forward oblique telescope and visual obturator.
Study NCT01218672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of the Prostate
Description: Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.
Study NCT00407147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor
Description: antibiotic treatment based on clinical decision making with traditional thought processes used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection.
Study NCT03401086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Kinesio Taping
Study NCT03218137 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine
Description: Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
Study NCT01481363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Talking Sense manual
Description: Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.
Study NCT01481363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual - communication information and advice
Description: Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
Study NCT03985267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based Swinging Effect Intervention
Description: Participants will receive psycho-education about mindfulness and how it operates. That will also assist patients to warm up for the actual intervention. Then the actual swinging effect intervention will commence respectively.
Study NCT03985267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness based Swinging Effect Intervention
Description: Participants will receive psycho-education about mindfulness and how it operates. That will also assist patients to warm up for the actual intervention. Then the actual swinging effect intervention will commence respectively.
Study NCT04468867 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Automated whole breast ultrasound
Description: This will be performed by a band 6 radiographer and will be done at baseline, post 2 cycles of chemotherapy and end of treatment chemotherapy
Study NCT04468867 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast MRI
Description: This will be performed by band 6 or 7 radiographer with MRI training
Study NCT00840411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER 500 mg tablets
Description: 1 x 500 mg
Study NCT00840411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIAXIN® XL 500 mg tablets
Description: 1 x 500 mg
Study NCT02740647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery
Study NCT02740647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml of 0.9% sodium chloride three times a day
Study NCT02149693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fidelity simulation and teamwork training
Study NCT02149693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional resuscitation training
Study NCT01026623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT01026623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01026623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT00944424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + High dose Vitamin D2
Description: Docetaxel + High dose Vitamin D2
Study NCT00944424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel + Standard dose Vitamin D2
Description: Docetaxel + Standard dose Vitamin D2
Study NCT02313064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXA-10
Description: Part A has sequential single ascending doses will be administered in up to 5 cohorts of subjects. Each cohort of subjects will be randomized to receive a single dose of CXA-10 or placebo in, a fasted state. Part B has 2 periods and subjects will receive two doses of the selected dose of CXA-10.
Study NCT02313064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CXA-10 placebo
Study NCT04852380 — intervention group
Intervention type: PROCEDURE
Intervention: PRP injections
Description: The 5 mL PRP concentrate was injected every week for three times, starting from recruitment. The patient was placed supine whit a knee flexion of 90°.All the procedures were carried out in an aseptic condition, injected in the knee soft spot through an anterior approach, using a 21-gauge needle.
Study NCT04236401 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: electrosurgery will be used for abdominal incision
Description: electrosurgery will be used to open anterior abdominal wall and electrosurgery will be used for heamostasis also
Study NCT04236401 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: scalpel will be used for abdominal incision
Description: scalpel will be used for abdominal wall incision and thread will be used for haemostsis
Study NCT04646213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Cancer and Living Meaningfully (CALM) Therapy
Description: 6 sessions of individualized CALM therapy
Study NCT03642548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifico
Description: Patients in BIFICO group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.
Study NCT03642548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
Study NCT03207880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-level pregnancy test
Description: Study participants will be instructed to perform a baseline MLPT immediately prior to administering the first dose of abortion medication and a second MLPT one week later to ascertain the follow-up hCG range. Any woman who obtains a stable or increasing hCG result, when comparing the baseline test result with the follow-up test result, will be instructed to contact safe2choose. Any woman who obtains a decrease in her hCG range, when comparing the baseline test result with the follow-up test result, will be informed that her abortion was a success and she is no longer pregnant.
Study NCT03235388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit filters
Description: Institutional implementation of audit filters
Study NCT02647177 — intervention group
Intervention type: OTHER
Intervention: Pancreatic Cyst Aspiration
Description: 10 CC of pancreatic cyst aspiration
Study NCT01781325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IBEHR
Description: physical therapy device to educate patients in physical therapy exercise performance
Study NCT00803686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral rsCT tablet
Description: On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
Study NCT00803686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Tablet
Description: Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
Study NCT00803686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral rsCT tablet
Description: Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
Study NCT00803686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fortical (rsCT) nasal spray
Description: Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
Study NCT03936556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed toothpaste
Description: Marketed stannous fluoride (0.454%) toothpaste
Study NCT03936556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marketed Cavity Protection Toothpaste
Description: Marketed sodium monofluorophosphate (0.76 %) toothpaste
Study NCT04486339 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: Stereotactic radiotherapy targets on the pulmonary vein ostium aiming to achieve pulmonary vein electrial isolation
Study NCT01060618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maraviroc + Trofile ESTA® (diagnose test)
Description: The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
Study NCT03500120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Seated saline infusion test
Description: Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Fludrocortisone suppression test:Patients received 0.1 mg oral fludrocortisone every 6 h for 4 days, together with slow-release potassium chloride and sodium chloride supplements.~Captopril challenge test:Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 1 h. Blood samples were drawn at time zero and 2 h after the challenge.
Study NCT03448107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Silver diamine fluoride (SDF)
Study NCT03448107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnishes
Description: Fluoride varnish (FV)
Study NCT03448107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnishes
Description: Fluoride varnish (FV)
Study NCT03448107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer
Description: Glass Ionomer Sealants (GC Fuji IX)
Study NCT01820793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Description: proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
Study NCT00949481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pregnancy Test
Description: Free pregnancy test strips will be supplied to family planning clinics
Study NCT00949481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Job aid
Description: A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.~Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see links for more information on the checklist)
Study NCT02372149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% intravenous immunoglobulin (IVIg)
Study NCT02372149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride
Study NCT01366079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Position change
Description: Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
Study NCT01366079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral
Description: In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
Study NCT01263704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
Study NCT01263704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 12.5 mg/m\^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
Study NCT00266877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKI-272
Description: 320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
Study NCT02619773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mupirocin ointment
Description: Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
Study NCT01263704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV Day 0 of Cycle 1, 500 mg/m\^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
Study NCT02298101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: FEV1, FVC assessment
Study NCT00927485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcumin (Curcumin)
Description: Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
Study NCT00927485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcumin (Curcumin)
Description: Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
Study NCT02548403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Asc
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Study NCT00927485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Factor Questionnaire
Description: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
Study NCT00927485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Risk Factor Questionnaire
Description: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
Study NCT02548403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Asc with simethicone
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
Study NCT04092751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA
Description: Single oral 20-mg dose of PRA on Day 1 AM
Study NCT04092751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078 plus PRA
Description: Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later
Study NCT03422770 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography
Description: Conventional transthoracic echocardiography will be performed, in addition 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.0) and in validated machine learning algorithms.
Study NCT03422770 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: Cardiac MRI will be performed. In all patients without contraindications a gadolinium-based contrast agent will be given.
Study NCT03422770 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test
Description: Conventional brachial venous blood samples will be drawn. Blood samples will be analyzed for markers of myocardial fibrosis at Oslo University Hospital.The findings will be related to imaging findings.
Study NCT00832039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium-selenite
Description: An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
Study NCT00832039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
Study NCT00832039 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Procalcitonin guided therapy
Description: Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline >=50%: no change in causal therapy; PCT drop from baseline \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT \<=1.0 ng/ml: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement >=50%: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.
Study NCT00832039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procalcitonin guided therapy
Description: Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline >=50%: no change in causal therapy; PCT drop from baseline \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT \<=1.0 ng/ml: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement >=50%: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.
Study NCT00545285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Surgical implantation of specific hip replacement components for treatment of osteoarthritis
Study NCT00927485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Three tubes of blood at visits 0, 4 and 12 months.
Study NCT00927485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Description: Three tubes of blood at visits 0, 4 and 12 months.
Study NCT00927485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsies (Sigmoidoscopy)
Description: Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
Study NCT00927485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Biopsies (Sigmoidoscopy)
Description: Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
Study NCT00927485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsies (Upper endoscopy)
Description: Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.